SEC Form 4 · accession 0001562180-17-003824
REGENXBIO Inc. · RGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Curran Simpson
Officer — SVP, Technical Operations
Period of report
Dec 7, 2017
Accepted (ET)
Dec 11, 2017 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590877
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 7, 2017 | M | 1,890 | $13.09 | A | 41,390 | D | |
| Common Stock | Dec 7, 2017 | M | 20,000 | $22.00 | A | 61,390 | D | |
| Common StockF2 | Dec 7, 2017 | S | 21,890 | $30.04 | D | 39,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $13.09 | Dec 7, 2017 | M | 1,890 | D | — | Jan 27, 2026 | Common Stock | 1,890 | 6,000 | D |
| Stock Option (Right to Buy)F4 | $22.00 | Dec 7, 2017 | M | 20,000 | D | — | Aug 30, 2025 | Common Stock | 20,000 | 210,500 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- F2This transaction was executed in multiple trades at prices ranging from $30.00 to $30.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3The previously granted option, representing a right to purchase a total of 10,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.
- F4The previously granted option, representing a right to purchase a total of 230,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 31, 2016, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.